Searched for
U.S. RESPIRATORY BUSINESS
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Fast-tracked power plants fuel AI boom, with little public scrutinyNew power plants are being built at an unprecedented speed to meet the growing demand of tech companies. These facilities, often fueled by ...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Southern California chemical tank at risk of exploding as 50,000 residents are ordered to evacuateA damaged chemical tank in Southern California shows a potential crack, possibly reducing explosion risk. However, 50,000 residents remain ...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- How South African scientists identified hantavirus on a cruise ship thousands of miles awayA cruise ship outbreak was identified as hantavirus. South African experts rapidly investigated a passenger evacuated with pneumonia. Initi...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- Lupin shares in focus after $250 million U.S. facility plan; Citi retains buy callLupin plans a significant $250 million investment over five years to establish a new manufacturing facility in Coral Springs, Florida. This...
- Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mnLupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FD...
- Some of the biggest splits in corporate AmericaMedtronic, the medical device maker plans to spin off its patient monitoring and respiratory interventions businesses into a new company, j...
Load More
